Eric Siemers

Company: Acumen Pharmaceuticals

Job title: Chief Medical Officer

Seminars:

Targeting Novel Forms of Amyloid to Improve Upon the Current Standard of Care & Reduce Implications of ARIA 1:30 pm

Outlining the promise of sabirnetug as a next generation treatment for AD Demonstrating significant reductions in ARIA-E and biomarker-driven signals of efficacy Implications for the future development of sabirnetugRead more

day: Conference Day One - Track Three

Panel Discussion: What Have we Learned from the Last 12 Months of Alzheimer’s Drug Development? 8:15 am

What have been the main obstacles to integrating first class of anti-amyloids into the treatment paradigm? What is the impact of ARIA on penetration of these new anti-amyloid therapies into market? What is the plan to better manage the burden of ARIA going forward? Shifting focus to new emerging therapies: From anti-inflammatory and anti-tau treatments…Read more

day: Conference Day One AM